Epoprostenol in pulmonary arterial hypertension

Bibliography

• Klob. Wien Wochenbl 1865;31:45
   Google Scholar
• Romberg E. Über sklerose der lungen arterie. Dtsch Arch Klin Med 1891;48:197-206
   Google Scholar
• Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-16
   PubMed Web of Science ®Google Scholar
• Group IPPHS: The international primary pulmonary hypertension study. Chest 1994;105:S37-41
   PubMed Web of Science ®Google Scholar
• Appelbaum L, Yigla M, Bendayan D, et al. Primary pulmonary hypertension in Israel: a national survey. Chest 2001;119:1801-6
   PubMed Web of Science ®Google Scholar
• Mac Gregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-9
   PubMed Web of Science ®Google Scholar
• Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997;24:81-5
   PubMed Web of Science ®Google Scholar
• Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest 1997;111:36-43
   PubMed Web of Science ®Google Scholar
• Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93
   PubMedGoogle Scholar
• Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74
   PubMed Web of Science ®Google Scholar
• Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford) 2000;39:1269-71
   PubMed Web of Science ®Google Scholar
• Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-50
   PubMed Web of Science ®Google Scholar
• Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000;9:338-42
   PubMed Web of Science ®Google Scholar
• Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990;17:1292-8
   PubMed Web of Science ®Google Scholar
• Alpert MA, Goldberg SH, Singsen BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983;68:1182
   PubMed Web of Science ®Google Scholar
• Hosoda Y, Suzuki Y, Takano M, et al. Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study. J Rheumatol 1987;14:826-30
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Sitbon O, et al. Prognostic Factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433
   PubMed Web of Science ®Google Scholar
• Humbert M, Nunes H, Sitbon O, et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001;22:459-75
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simmoneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36
   PubMed Web of Science ®Google Scholar
• Gryglewski RJ. Prostaglandins, platelets, and atherosclerosis. CRC Crit Rev Biochem 1980;7:291-338
   PubMed Web of Science ®Google Scholar
• Badesch DB, Abman SH, Simmonneau G, et al. Medical therapy for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28
   PubMed Web of Science ®Google Scholar
• Mc Laughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8
   PubMed Web of Science ®Google Scholar
• Barst R, Berman-Rosenzweig E, Horn E, et al. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. Morb Mortal Wkly Rep 2007;56(8):170-2
   PubMedGoogle Scholar
• Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:891-901
   PubMed Web of Science ®Google Scholar
• Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5
   PubMed Web of Science ®Google Scholar
• Bunting S, Gryglewski R, Moncada S, et al. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and celiac arteries and inhibits platelet aggregation. Prostaglandins 1976;12:897-913
   PubMed Web of Science ®Google Scholar
• Moncada S, Herman AG, Higgs EA, et al. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium. Thromb Res 1977;11:323-44
   PubMed Web of Science ®Google Scholar
• Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 1979;30:293-331
   Web of Science ®Google Scholar
• Utaba FB, Moncada S, Vane JR. The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time. Thromb Haemost 1979;41:425-35
   PubMed Web of Science ®Google Scholar
• Aiken JW, Gorman RR, Shebuski RJ. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 1979;17:483-94
   PubMedGoogle Scholar
• Szczeklik A, Gryglewski RJ, Nizankowski R, et al. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun 1978;10:545-56
   PubMedGoogle Scholar
• Whittle BJR. Role of prostaglandins in the defense of the gastric mucosa. Brain Res Bull 1980;5(Suppl 1):7-14
   PubMedGoogle Scholar
• Moncada S, Vane JR. The prostacyclin/thromboxane balance and cardiovascular disease. In: Isselbacher KJ. Symposium celebrating the Harvard Medical School bicentennial. New York: John Wiley & sons; 1982:83-113
   Google Scholar
• Vane JR. Clinical potential of prostacyclin. Adv Prostaglandins Thromboxane Leukot Res 1983;11:449-56
   PubMedGoogle Scholar
• Demling RH, Smith M, Gunther R, et al. The effect of prostacyclin infusions on endotoxin-induced lung injury. Surgery 1981;89:257-63
   PubMed Web of Science ®Google Scholar
• Araki H, Lefer AM. Cytoprotective actions of prostacyclin during hypoxia in isolated perfused cat liver. Am J Physiol 1980;238(Suppl):H176-81
   Google Scholar
• Jugdutt BF, Hutchins GM, Bulkley BH, et al. Infarct size reduction by prostacyclin after coronary artery occlusion in conscious dogs. Clin Res 1979;27:177A
   Google Scholar
• Ogletree ML, Lefer AM, Smith JB, et al. Studies on the cytoprotective effect of prostacyclin in acute myocardial ischaemia. Eur J Pharmacol 1979;56:95-103
   PubMed Web of Science ®Google Scholar
• Ribeiro LGT, Brandon TA, Hopkins DG, et al. Prostacyclin in experimental myocardial ischaemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol 1981;47:835-40
   PubMed Web of Science ®Google Scholar
• Starnes VA, Primm RK, Woosley RL, et al. Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs. J Cardiovasc Pharmacol 1982;4:765-9
   PubMed Web of Science ®Google Scholar
• Ohlendorf R, Perzborn E, Schrör K. Prevention of infarction-induced decrease in circulating platelet count by prostacyclin. Thromb Res 1980;19:447-53
   PubMed Web of Science ®Google Scholar
• Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001;138:287-97
   PubMed Web of Science ®Google Scholar
• Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle cell proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26;194-201
   PubMed Web of Science ®Google Scholar
• Chow KB, Jones RL, Wise H. Protein kinase A-dependent coupling of mouse prostacyclin receptors to Gi is cell-type dependent Eur J Pharmacol 2003;474:7-13
   PubMed Web of Science ®Google Scholar
• Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000;1483:285-93
   PubMed Web of Science ®Google Scholar
• Bhattacharya M, Peri K, Ribeiro-Da-Silva A, et al. Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 1999;274:15719-24
   PubMed Web of Science ®Google Scholar
• Bhattacharya M, Peri KG, Almazan G, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998;95:15792-97
   PubMed Web of Science ®Google Scholar
• Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275-80
   PubMed Web of Science ®Google Scholar
• Hatae T, Wada M, Yokoyama C, et al. Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 2001;276:46260-7
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997;94:4318-23
   PubMed Web of Science ®Google Scholar
• Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 2000;14:1962-75
   PubMed Web of Science ®Google Scholar
• Gray JP, Burns KA, Leas TL, et al. Regulation of peroxisome proliferator-activated receptor alpha by protein kinase C. Biochemistry 2005;44:10313-21
   PubMed Web of Science ®Google Scholar
• Christman BW. Lipid mediator dysregulation in primary pulmonary hypertension Chest 1998;114(Suppl 3):205S-7S
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32
   PubMed Web of Science ®Google Scholar
• Geraci MW, Gao B, Sheperd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103(11):1509-15
   PubMed Web of Science ®Google Scholar
• Tahara N, Kai H, Niiyama H, et al. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther 2004;15(12):1270-8
   PubMed Web of Science ®Google Scholar
• Rich S, McLaughlin V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-7
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Pullamsetti SS, Breitenbach SC, et al. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res 2007;8:4
   PubMedGoogle Scholar
• Oikawa M, Kagaya Y, Otani H, et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 2005;45:1849-55
   PubMed Web of Science ®Google Scholar
• Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86
   PubMed Web of Science ®Google Scholar
• Kerbaul F, Brimioulle S, Rondelet B, et al. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 2007;175:846-50
   PubMed Web of Science ®Google Scholar
• Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-7
   PubMed Web of Science ®Google Scholar
• Wauthy P, Abdel Kafi S, Mooi WJ, et al. Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension. J Thorac Cardiovasc Surg 2003;126:1434-41
   PubMed Web of Science ®Google Scholar
• Sakuma M, Demachi J, Nawata J, et al. Epoprostenol infusion therapy changes angiographic findings of pulmonary arteries in patients with idiopathic pulmonary arterial hypertension. Circ J 2008;72:1147-51
   PubMed Web of Science ®Google Scholar
• Pola R, Gaetani E, Flex A, et al. Comparative analysis of in vivo angiogenic properties of stable prostacyclin analogues: A possible role for peroxisome proliferator – activated receptors. J Mol Cell Cardiol 2004;36:363-70
   PubMed Web of Science ®Google Scholar
• Miyahara Y, Ohnishi S, Obata H, et al. Beraprost sodium enhances neovascularisation in ischaemic myocardium by mobilizing bone marrow cells in rats. Biochem Biophys Res Commun 2006;349:1242-9
   PubMed Web of Science ®Google Scholar
• Herner SJ, Mauro LS. Epoprostenol in primary pulmonary hypertension. Ann Pharmacother 1999;33:340-7
   PubMed Web of Science ®Google Scholar
• Brash AR, Jackson EK, Saggese CA, et al. Metabolic dispostion of prostacyclin in humans. J Pharmacol Exp Ther 1983;226:78-87
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7
   PubMed Web of Science ®Google Scholar
• Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-8
   PubMedGoogle Scholar
• Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomised trial. Ann Intern Med 1990;112:485-91
   PubMed Web of Science ®Google Scholar
• Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health registry on primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-30
   PubMedGoogle Scholar
• Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-8
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8
   PubMed Web of Science ®Google Scholar
• Robbins IM, Christman BW, Newman JH, et al. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998;114:1269-75
   PubMed Web of Science ®Google Scholar
• Conte JV, Gaine SP, Orens JB, et al. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998;17:679-85
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, Mc Goon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34
   PubMed Web of Science ®Google Scholar
• Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999;13:1351-6
   PubMed Web of Science ®Google Scholar
• Klings ES, Hill NS, Ieong MH, et al. Systemic sclerosis associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999;42:2638-45
   PubMed Web of Science ®Google Scholar
• Mc Laughlin VV, Genther DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130:740-3
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65
   PubMed Web of Science ®Google Scholar
• Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-50
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Swanson KL. How should we treat portopulmonary hypertension? Eur Respir J 2006;28:466-7
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-43
   PubMed Web of Science ®Google Scholar
• Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28(6):1195-203 [Epub 9 Aug 2006]
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Mc Laughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63
   PubMed Web of Science ®Google Scholar
• Voswinckel R, Enke B, Reichenberger F, et al. Favourable effects of inhaled treprostinil in severe pulmonary hypertension. J Am Coll Cardiol 2006;48:1672-81
   PubMed Web of Science ®Google Scholar
• Higenbottam TW, Butt AY, Dinh-Xuan AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998;79:175-9
   PubMed Web of Science ®Google Scholar
• Ewert R, Opitz CF, Wensel R, et al. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 2007;96:211-7
   PubMed Web of Science ®Google Scholar
• Tapson VF, Gomberg-Maitland M, Mc Laughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective multicentre open label 12 week trial. Chest 2006;129:683-8
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9
   PubMed Web of Science ®Google Scholar
• Simonneau G, Burgess G, Collings L, et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;3:A58
   Google Scholar
• Simonneau G, Rubin LJ, Galiè N, et al. Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2007;175:A300
   Google Scholar
• Abid F, Delgado O, Rahaghi FF. A cost analysis of the treatment of pulmonary arterial hypertension. Chest 2007;132:632S
   Google Scholar
• Narine L, Hague LK, Walker JH, et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension, Curr Med Res Opin 2005;21(12):2007-16
   PubMed Web of Science ®Google Scholar
• Einarson TR, Granton JT, Vincente C, et al. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J 2005;12(8):419-25
   PubMedGoogle Scholar
• Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idipathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-10
   PubMed Web of Science ®Google Scholar
• Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29:469-75
   PubMed Web of Science ®Google Scholar